You are here

Home » Content

MDAH-2774 insan Over Kanseri Üç Boyutlu Hücre Kültüründe Farklı ilaç Etkilerinin Nitrik Oksit Sentaz Değişiklikleri ile incelenmesi

Examination of the different medicine effects at MDAH-2774 human ovary cancer three dimensional cell culture with nitric oxide synthase changing

Journal Name:

  • Cerrahpaşa Tıp Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objectives: The purpose of our study is to examine the effects of the various medicines at the three dimensional MDAH-2774 human ovary cancer culture with cell proliferation and nitric oxide synthase changing. Methods: Using of medicines at the two dimensional cultures jointly or severally was examined by immunohystochemical method in terms of cell increasing at the 24th, 48th, 72nd and 96th hours and in terms of activities of excitable (inducible) nitric oxide synthase and endothelial nitric oxide synthase at the tree dimensional cultures. Results: Using of these medicines in Paracetamol, gemsitabine and Gemsitabine + Paracetamol and Gemsitabine + Resveratrol combination groups, reduced the number of the cells at all hours according to the control (p<0,05). When performed immunohystochemical analyses were individually compared with the cells of MDAH-2774 or medicine combination, it indicated that caused increasing at inducible nitric oxide synthase and endothelial nitric oxide synthase immunoreactivity. Immunoreactivity increased markedly at the 96th hour in comparison with the 24th hour. Conclusion: Using of the medicines one by one or in combination, reduced the cell proliferation at all hour time zones and increased inducible nitric oxide synthase and endothelial nitric oxide synthase activity.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: MDAH-2774 insan over kanseri iki ve üç boyutlu hücre kültüründe farklı ilaç etkilerinin hücre proliferasyonu ve nitrik oksit sentaz değişiklikleri ile incelenmesidir. Yöntem: iki boyutlu kültürlerde ilaçların ayrı ayrı ve birlikte kullanımları 24, 48, 72 ve 96. saatlerde hücre çoğalması açısından, Üç boyutlu kültürlerde 24 ve 96. saatlerde uyarılabilir (indüklenebilir) nitrik oksit sentaz ve endotelial nitrik oksit sentaz aktivitesi açısından immünohistokimyasal yöntemle incelendi. Bulgular: Parasetamol, Gemsitabine ve Gemsitabine + Parasetamol ve Gemsitabine + Resveratrol kombinasyon gruplarında bu ilaçların kullanılması kontrole göre tüm saatlerde hücre sayısını anlamlı bir şekilde azalttı (p< 0,05). Yapılan immunohistokimyasal analizler Gemsitabine’in MDAH-2774 hücreleri ile tek başına veya ilaç kombinasyonu ile karşılaştırıldığında nitrik oksit sentaz ve endotelial nitrik oksit sentaz immunoreaktivitesinde artışa neden olduğunu göstermiştir. İmmunoreaktivite 96 saatte, 24 saate göre belirgin olarak artmıştır. Sonuç: İlaçların tek tek ve kombinasyon halinde kullanımı tüm saat dilimlerinde hücre proliferasyonunu azaltmış, nitrik oksit sentaz ve endotelial nitrik oksit sentaz aktivitesini artırmıştır.
FULL TEXT (PDF): 
PDF icon arastirmax-mdah-2774-insan-over-kanseri-uc-boyutlu-hucre-kulturunde-farkli-ilac-etkilerinin-nitrik-oksit-sentaz-degisiklikleri-ile-incelenmesi.pdf
  • 4
88-96
  • Turkish

REFERENCES

References: 

Kaynaklar
1. Altınöz MA, Bilir A. Inflamation, nonsteroid and
steroid anti-inflammatory agents and ovarian cancer
In: Bardos PA, ed. Treatment of Ovarian Cancer. New
York: Nova Science Publishers; 2005. p. 97-111.
2. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer
metastasis and angiogenesis: an imbalance of positive
and negative regulation. Cell 1991; 64: 327-336.
3. Kayaalp O. Rasyonel Tedavi Yönünden Tibbi
Farmakoloji. Ankara: Güneş Basımevi; 2000.
4. Gemcitabine®, Preparat reçetesi ( Lilly).
5. Ali S, El-Rayes BF, Aranha O, Sarkar FH, Philip PA.
Sequence dependent potentiation of gemcitabine by
flavopiridol in human breast cancer Cells. Breast
Cancer Res Treat 2005; 90: 25-31.
6. İkizler M, Dernek S, Erkasap N, Kaygısız Z, Sevin B,
Kural T. The hemodynamic efficacy of resveratrol on
reperfüzyon. Injury in isolated rat hearts. Türk Gö¤üs
Kalp Damar Cerrahisi Dergisi 2003; 11: 91-99.
7. Wenzel E, Somoza V. Metabolism and bioavailability
of trans-resveratrol. Mol Nutr Food Res 2005; 4: 49.
8. Aggarwal BB, Shishir S. Molecular targets of dietary
agents for prevention and therapy of cancer. J
Biochem Pharmacol 2006; 71: 1397-1421.
9. ‹gnorro JJ, Byrns RE, Wood KS. Biochemical and pharmacological
propeties of endothelium-derived relaxing
factor and its smilarity to nitric oxide radicals. In:
Vanhoutte PM, ed. Vasodilatation. New York: Raven
Press; 1998. p. 427-436.
10. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide
release accounts for the biological activity of
endotelium derived relaxing factors. Nature 1988;
327: 524-526.
11. Vakkala M, Kahlos K, Lakkari E, Paakko P. Inducible
nitric oxide synthase expression, apoptosis, and angiogenesis
in in situ and invasive breast carsinoma. Clin
Canser Res 2000; 6: 2408-2416.
12. fiahin F, Avcu F, Saydam G, ve ark. Kırmızı üzüm
çekirdeği ekstraktı ve ana bileşenlerinden resveratrol
ve boraks malign hücre dizileri üzerinde sitotoksik etki
göstermektedir. Turkish Journal of Haematology;
2004; 21 Suppl 3: 53-54. [Abstract]
13. http://en.wikipedia.org/wiki/Resveratrol
14. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A,
Fernandez-Salguero PM, Castellon EA. Mechanisms
involved in resveratrol-induced apoptosis and cell
cycle arrest in prostate cancer-derived cell lines. J
Androl 2006; 7: 333-335.
15. Riles WL, Erickson J, Nayyar S, Atten MJ, Attar BM,
Holian O. Resveratrol engages selective apoptotic signals
in gastric adenocarcinoma cells. World J
Gastroenterol 2006; 12: 5628-5634.
16. Turna H., Demir G. Pankreas Kanseri Tedavisine
Medikal Onkolojik Yaklaşım. İstanbul: İ.Ü. Cerrahpaşa
Tıp Fakültesi Sürekli Tıp Eğitim Etkinlikleri; 2002. s.
231-236.
17. Zhu GH, Wong BCY, Ching CK, Lai KC, Lam SK.
Differential apoptosis by indomethacin in gastric
epithelial cells Trough the constiyuve expression of
wild-Type p53 and/or Up-regulation of c-myc.
Biochem Pharmacol 1999; 58: 193-200.
18. Bernardi A, Jacques- Silva MC, Delgada- Canedo A,
Lenz G, Battastini M. Nonsteroidal anti- inflammatory
drugs inhibit the growth of C6 and U138-MG glioma
Cell Lines. Eur J Pharmacol; 2006; 532: 214-222.
95
Cerrahpaşa Tıp Derg 2009; 40(3): 88-96
96
fi. Ayla, G. Öktem, A. Bilir
19. Joki T, Carrol RS, Dunn IF, Zhang J, Abe T, Black PM.
Assesment of alteration in gene expression in reccurrent
malignant glioma after radiotherapy using complemantary
deoxyribonucleic acid microarrays.
Neurosurgery 2001; 48: 195-201.
20. Özdemirler G, Aykaç G, Uysal M, et al. Liver lipid peroxidation
and glutathione-related defence enzyme
systems in mice treated with paracetamol. J Appl
Toxicol 1994; 14: 297-299.
21. Bilir A, Altinoz MA, Atar E, Erkan M, Ayd›ner A.
Acetaminophen modulations of chemotherapy efficacy
in MDAH 2774 human endometrioid ovarian cancer
cells in vitro. Neoplasma 2002; 49: 38-42.
22. Yip-Schneider TM., Sweeney J, Jung S, Crowell PL,
Marshall MS. Cell cycle effects of nonsteroidal antiinflammatory
drugs and enhanced growth inhibition in
combination with gemcitabine in pancreatic carcinoma
cells. J Pharmacol Exp Ther 2001; 298: 976-985.
23. Öktem G. MCF-7 ‹nsan Meme Kanseri Hücre Hatt›nda
Doksorubisin ve Dositakselin Sitotoksisitesi ve ‹ndüklenebilir
Nitrik Oksit Sentaz Ekspresyonu Üzerine
Etkileri. Uzmanl›k Tezi. ‹zmir: Ege Ü. T›p Fakültesi
Histoloji ve Embriyoloji Anabilim Dal›: 2002.
24. Nathan C. Nitric oxide as a secretory product of mammalian
cells. FASEB J 1992; 6: 3051-3064.
25. Farais-Eisner R, Sherman MP, Aeberhard E, et al. Nitric
oxide is an important mediator for tumorocidal activity
in vivo. Proc Natl Acad Sci USA 1994; 91: 9407-
9411.
26. Stuehr DJ, Nathan JF. Nitric oxide: a macrophage
product responsible for cytostasis and respiratory inhibition
in tumor target cells. J Exp Med 1989; 169:
1543-1545.
27. Thomsen LJ, Lawton FG, Knowles RG. Nitric oxide
synthase activity in human gynecological cancer.
Cancer Res 1994; 54: 1352-1354.
28. Thomsen LJ, Scott JMJ, Topley P, Knowles RG, Keerie
AJ, Frend AJ. Selective inhibition of inducible nitric
oxide sythase inhibits tumor growth in vivo: studies
with 1400 W, a novel inhibitor. Cancer Res 1997; 57:
3300-3304.
29. Xie K, Huang S, Dong Z, Gutman M. Direct correlation
between expression of endogenous inducible
nitric oxide synthase and regression of M5076 reticulum
cell sarcoma hepatic metastases in mice treated
with liposomes containing lipopeptide CGP 31362.
Cancer Res 1995; 55: 3123-3131.
30. Thomsen LL, Miles DW. Role of nitric oxide in tumor
progression: Lessons from human tumors. Cancer and
Met Rew 1998; 17: 107-118.
31. Lechner M, Lirk P,Rieder J. Inducible nitric oxide synthase
(iNOS) in tumor biology: the two sides of the
same coin. Semin Cancer Biol 2005; 15: 277-89.
32. Darh A, Brindley JM, Stark C, Citro ML, Keefer LK.
Nitric oxide does not mediate but inhibits transformation
and tumor phenotype. Mol Cancer Ther 2003; 2:
1285-1293.
33. Zeybek DN, Inan S, Ekerb›cer N, Vatansever SH. The
effects of gemcitabine and vinoralbine on inducible
nitric oxide synthase (iNOS) and endothelial nitric
oxide synthase (eNOS) distribution of MCF-7 breast
cancer cells. Acta Histochem 2009;
doi:10.1016/j.acthis.2009.07.006
34. Cooper MG, Hausman ER. Hücre - Moleküler
Yaklaşım. Çev. ed.: Sakızlı M, Atabey N. İzmir: İzmir
Tıp Kitabevi; 2006. s. 664-665.

Thank you for copying data from http://www.arastirmax.com